glp-1 obesity drug news october 21 2025 Americans Need More Information About Weight Loss Drugs GLP-1 drug coverage for obesity

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society

[DOI] [PubMed] [Google Scholar] 11.Drucker DJ

**Health plan client adoption is typically lower due to higher rates of customization

Tirzepatide has received approval for use in patients with T2D following several phase 3 studies testing and demonstrating its marked anti-hyperglycemic efficacy and positive actions on multiple cardiovascular risk factors, associated with an excellent safety profile [2, 3]

Significant weight reduction was seen, but bone mineral density (BMD) did not change

Colvin et al., 2020) and decreases alcohol self-administration, without affecting the extinction-induced reacquisition of alcohol self-administration or the motivation to consume alcohol (Dixon et al., 2020)